ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2603

Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders

Jeffrey Crowley1, Kim A Papp2, Chih-ho Hong3, Jeff Parno4, Alan M Mendelsohn4, Qing Li5 and Nicole Cichanowitz5, 1Bakersfield Dermatology, Bakersfield, CA, 2Probity Medical Research, Waterloo, ON, Canada, 3University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, 5Merck & Co., Inc., Kenilworth, NJ

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Biologics, clinical trials and psoriasis, IL-23

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development, may benefit patients (pts) who do not adequately respond to ETN. The efficacy of tildrakizumab (TIL), a high-affinity, humanized, anti–interleukin-23p19 monoclonal antibody, was evaluated in pts with moderate to severe chronic plaque psoriasis who were partial responders (Psoriasis Area and Severity Index [PASI] ≥50–<75) or nonresponders (PASI <50) to ETN and were subsequently rerandomized to TIL in a phase 3 trial.

Methods: Pts with psoriasis (≥10% body surface area, Physician’s Global Assessment [PGA] ≥3, and PASI ≥12) participated in a 3-part, 52-week, randomized controlled trial (reSURFACE 2; NCT01729754). In Part 1 (Week [W]0–W12), pts were randomized to subcutaneous placebo (PBO), TIL 100 mg, or TIL 200 mg administered at W0 and W4, or ETN 50 mg administered 2x/wk. In Part 2 (W12–W28), TIL and ETN pts remained on the same treatment (TIL administered at W16; ETN 1x/wk), whereas PBO pts were rerandomized to TIL 100 or 200 mg. In Part 3 (W28–W52), ETN responders (PASI ≥75) were discontinued; partial and nonresponders were switched to TIL 200 mg (administered at W32, W36, W48). For this post hoc analysis, the proportions of pts (±SD) with PASI responses and PGA response (score of 0 [“clear”] or 1 [“minimal”] with at least a 2-grade score reduction from baseline) were determined at W52.

Results: In all, 1090 pts were randomized. Of the 313 pts randomized to ETN, by W28 there were 83 partial responders and 39 nonresponders. At W52 (after 20 weeks of TIL treatment) for ETN partial responders, 75%±5%, 34%±5%, 15%±4%, and 58%±5% had achieved PASI 75, 90, 100, and PGA responses, respectively, with TIL 200-mg treatment. At W52 for ETN nonresponders, 54%±6%, 31%±5%, 10%±3%, and 56%±5% had achieved PASI 75, 90, 100, and PGA responses, respectively, with TIL 200-mg treatment. Adverse events were similar in pts switched from ETN to TIL at W28 compared with the pts who were maintained on TIL through W52.

Conclusion: A substantial portion of patients with moderate to severe chronic plaque psoriasis who are partial responders or nonresponders to ETN may respond after switching to treatment with TIL 200 mg. TIL may be a reasonable option for those with inadequate response to ETN.

Analyses presented at the American Academy of Dermatology Annual Meeting, February 16–20, 2018, San Diego, CA, USA.


Disclosure: J. Crowley, AbbVie, Amgen, Boehringer Ingelheim, Janssen, Lilly, MC2 Therapeutics, Merck & Co, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Sun Pharmaceuticals Industries Inc, UCB, and Verrica Pharmaceuticals, 2,AbbVie, Amgen, Celgene, Dermira, Lilly, Novartis, Sun Pharmaceutical Industries, Inc and UCB, 5,AbbVie, Amgen, Janssen, Lilly, Novartis, Regeneron, and Sanofi, 8; K. A. Papp, AbbVie, Akros, Allergan, Amgen, Anacor, Arcutis, Astellas, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Galderma, Genentech, GSK, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Merck Sharp & Dohme, Me, 2,AbbVie, Akros, Amgen, Arcutis, Astellas, Astra Zeneca, Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, CanFite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, Janssen, Kyowa Hakko Kirin, Leo, Meiji Seik, 5,AbbVie, Amgen, Astellas, Celgene, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin, Leo, Merck Sharp & Dohme, Novartis, Pfizer, Valeant, 8; C. H. Hong, Amgen, AbbVie, Eli Lilly, Janssen, Merck, Novartis, GlaxoSmithKline, Celgene, UCB, 2,Amgen, AbbVie, Eli Lilly, Janssen, Novartis, GlaxoSmithKline, Celgene, Sun Pharmaceutical Industries, Inc, 5,Amgen, AbbVie, Eli Lilly, Janssen, Novartis, Celgene, 8; J. Parno, Sun Pharmaceutical Industries, Inc., Kyowa Kirin Pharmaceutical Development, Inc., 5; A. M. Mendelsohn, Sun Pharmaceutical Industries Inc, 3; Q. Li, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, 3; N. Cichanowitz, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, 1, 3.

To cite this abstract in AMA style:

Crowley J, Papp KA, Hong CH, Parno J, Mendelsohn AM, Li Q, Cichanowitz N. Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-tildrakizumab-in-etanercept-partial-responders-or-nonresponders/. Accessed May 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-tildrakizumab-in-etanercept-partial-responders-or-nonresponders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences